Avanzcare, the subsidiary of Al Sawari Holding in the medical sector, and the UK-headquartered Indivior, a leading global pharmaceutical company specialised in addiction treatment, have entered into a new supply agreement.
Under this agreement, which was signed at the recently held high-profile Qatar-UK Investment Forum, Avanzcare would be the sole distributor of London Stock Exchange-listed Indivior’s products to supply Qatar health institutions for the treatment of opioid dependent patients.
With this agreement, Avanzcare would therefore be able to meet the latent need in Qatar for the delivery of highly effective, novel treatment solutions. It would be supplying Indivior’s Suboxone (buprenorphine and naloxone) Sublingual Film, Suboxone (buprenorphine and naloxone) sublingual Tablet, a buprenorphine-based treatment for opioid dependence recognised by health authorities around the world as vital treatment options of opioid-dependent patients. Avanzcare would be contributing to the recovery of patients suffering from addiction and helping them to be reintegrated into their communities and families. “Avanzcare is committed to play an important role in ameliorating the perception and the stigma related to patients suffering from addiction in Qatar with the help of designated authorities and health bodies,” its spokesman said.